Government doctors to reconsider whether UK should vaccinate all children against deadly disease meningitis B
Britain has fourth highest meningitis B levels in Europe
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Government doctors will reconsider whether the UK should vaccinate all children against the deadly disease meningitis B, having previously said immunisation would not be cost-effective.
The Joint Committee on Vaccination and Immunisation (JCV) said that “a number of key issues and themes” had emerged from a consultation following their announcement in July, and pledged “a further careful review of the evidence”.
The UK has the fourth highest meningitis B levels in Europe. There were 613 cases in 2011-12, and 33 deaths – including 15 children under four-years-old. One in 10 survivors suffer from major physical or neurological disabilities.
A vaccine, Bexsero, developed by the Swiss pharmaceutical giant Novartis, has been licenced for use in Europe. Evidence suggests it can protect against 73 per cent of the bacteria that cause the disease.
In July, the JCVI said that giving the vaccine to children in the UK was unlikely to be cost-effective – a decision that was met with dismay by meningitis patients and their families.
Christopher Head, chief executive of the Meningitis Research Foundation, said it was “encouraging” that the JCVI was reassessing the evidence and called on people to contact their MPs to highlight the impact of the disease.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments